2022 annual financial data
Inhibrx Biosciences 2022 Net margin
Direct answer
Net margin was -6,625.27%.
Operating income was -129,117,000 USD and net income was -145,226,000 USD.
Operating cash flow was -115,301,000 USD.
Get free Inhibrx Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,192,000 USD
- Operating income
- -129,117,000 USD
- Net income
- -145,226,000 USD
- Operating cash flow
- -115,301,000 USD